Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

Core Insights - Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain, marking a significant step towards regulatory approval [1][2][3] - The company is on track to submit an Investigational Device Exemption (IDE) to the FDA, with plans to commence U.S. clinical trials in 2026 if approved [1][3] - Autonomix's technology platform has the potential to address multiple high-need therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [4][7] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases related to the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [6][7] - The company's initial development efforts are concentrated on pain management, specifically targeting pancreatic cancer, which currently lacks effective treatment options [7] Research Institute Collaboration - The GLP study is being conducted at CBSET, a leading translational research institute in Massachusetts, known for its high-quality biomedical research services [5]